Is Aclaris Therapeutics, Inc. overvalued or undervalued?

As of 12 March 2018, Aclaris Therapeutics, Inc. has moved from a valuation grade of "does not qualify" to "risky." The company is currently considered overvalued based on its financial metrics. Key ratios include a Price to Book Value of 1.15, an EV to Sales ratio of 3.42, and a ROCE of -137.21%.
In comparison to its peers, Aclaris has a significantly negative P/E ratio of -3.53, while Tarsus Pharmaceuticals, Inc. and Kiniksa Pharmaceuticals Ltd. report P/E ratios of -16.08 and -69.27, respectively. The negative EV to EBITDA ratios across the board, including Aclaris at -1.14, indicate a challenging financial position. Despite a recent uptick in stock performance over the past month, the year-to-date return of -43.95% starkly contrasts with the S&P 500's 2.44%, reinforcing the notion of overvaluation.